Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histological proven prostate cancer, locally advanced or metastatic and scheduled to receive hormonal deprivation therapy
Life expectancy of more than 9 months
Documented testosterone levels of ≥ 125 ng/dl measured by any laboratory or on site within the previous 6 months
You may not be if
Has a history of hypersensitivity to the Investigational Medicinal Product or drugs with a similar chemical structure
Has previously received a GnRH analogue, estrogens or a steroidal anti -androgen within the last year preceding the study
Concomitant anti-coagulation treatment
Patient who underwent an orchidectomy or who is scheduled to receive an orchidectomy during the course of this study
Patient with known spinal medullar compression
Clareo Health | Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
